Odyssey Therapeutics, Inc. SEC filings ODTX

Odyssey Therapeutics, Inc. has 72 filings in SEC EDGAR's recent list, going back to Oct 14, 2021. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.

Odyssey Therapeutics, Inc. SEC filings
Form Description Filed Period
EFFECT Filing May 7, 2026 —
CERT Filing May 7, 2026 —
8-A12B Filing May 5, 2026 —
DRS/A Filing Apr 3, 2026 —
DRS/A Filing Mar 16, 2026 —
DRS Filing Feb 6, 2026 —
D Filing Dec 4, 2025 —
RW Filing Jun 9, 2025 —
DRS/A Filing Dec 5, 2024 —
DRS/A Filing Nov 18, 2024 —
DRS Filing Oct 7, 2024 —
D/A Filing Aug 14, 2024 —
D Filing Dec 15, 2023 —
D Filing Oct 27, 2022 —
D Filing Oct 14, 2021 —

Showing 15 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
ODTX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Boston, MA
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
1882782

Other Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.